SP
LLY icon

Sarasin & Partners’s Eli Lilly LLY Stock Holding History

Sarasin & Partners’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133M Sell
110,831
-11,349
-9% -$11.6M 1.56% 23
2026
Q1 		$112M Sell
122,180
-9,317
-7% -$9.45M 1.37% 26
2025
Q4 		$141M Sell
131,497
-8,858
-6% -$8.47M 1.47% 29
2025
Q3 		$102M Sell
140,355
-97,438
-41% -$72.5M 1% 31
2025
Q2 		$185M Buy
237,793
+9,735
+4% +$7.56M 1.85% 23
2025
Q1 		$188M Sell
228,058
-27,437
-11% -$22.8M 2.04% 22
2024
Q4 		$197M Buy
255,495
+15,260
+6% +$12.6M 2.18% 18
2024
Q3 		$213M Sell
240,235
-74,186
-24% -$66.7M 2.01% 24
2024
Q2 		$285M Buy
314,421
+38,597
+14% +$30.9M 2.52% 18
2024
Q1 		$215M Buy
275,824
+28,335
+11% +$20.2M 2.11% 21
2023
Q4 		$144M Buy
247,489
+237,478
+2,372% +$139M 1.59% 27
2023
Q3 		$5.38M Buy
+10,011
New +$5.16M 0.07% 61
2023
Q2 		– Sell
-157,150
Closed -$43.2M – 89
2023
Q1 		$43.2M Buy
157,150
+127,754
+435% +$43.1M 0.23% 61
2022
Q4 		$10.8M Sell
29,396
-22,244
-43% -$7.89M 0.14% 60
2022
Q3 		$16.7M Sell
51,640
-32,319
-38% -$10.2M 0.23% 58
2022
Q2 		$27.2M Sell
83,959
-43,795
-34% -$13.1M 0.34% 52
2022
Q1 		$36.6M Hold
127,754
– – 0.37% 54
2021
Q4 		$35.3M Hold
127,754
– – 0.32% 53
2021
Q3 		$29.5M Hold
127,754
– – 0.3% 57
2021
Q2 		$29.3M Buy
127,754
+5,481
+4% +$1.1M 0.31% 52
2021
Q1 		$22.8M Sell
122,273
-30,696
-20% -$6M 0.27% 53
2020
Q4 		$25.8M Buy
152,969
+23,081
+18% +$3.45M 0.34% 52
2020
Q3 		$19.2M Buy
129,888
+72,299
+126% +$11.2M 0.28% 52
2020
Q2 		$9.46M Hold
57,589
– – 0.15% 64
2020
Q1 		$7.99M Buy
57,589
+13,049
+29% +$1.79M 0.16% 64
2019
Q4 		$5.85M Hold
44,540
– – 0.09% 90
2019
Q3 		$4.98M Buy
44,540
+17,136
+63% +$1.91M 0.08% 90
2019
Q2 		$3.04M Buy
27,404
+1,191
+5% +$140K 0.05% 109
2019
Q1 		$3.4M Hold
26,213
– – 0.07% 94
2018
Q4 		$3.03M Sell
26,213
-7,088
-21% -$792K 0.07% 93
2018
Q3 		$3.57M Buy
+33,301
New +$3.33M 0.07% 98

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
ONB
Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
GIM
Goelzer Investment Management Carmel, Indiana $2.29B AUM 39.12% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sarasin & Partners's LLY Position: Q2 2026 in Review

Sarasin & Partners reduced its Eli Lilly (LLY) stake by 9.3% in Q2 2026, selling an estimated $11.6M and leaving 110,831 shares worth $133M. The position accounts for 1.56% of the portfolio, ranked #23.

Sarasin & Partners first reported a position in LLY in Q3 2018 and has held it in 31 quarters since. The position peaked at $285M in Q2 2024. 1,613 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Sarasin & Partners held 110,831 shares of Eli Lilly worth $133M as of Q2 2026.
  • Sarasin & Partners sold 11,349 Eli Lilly shares in Q2 2026, an estimated $11.6M.
  • Eli Lilly made up 1.56% of Sarasin & Partners's portfolio in Q2 2026, its #23 holding.
  • Sarasin & Partners first reported a position in Eli Lilly in Q3 2018 and has held it in 31 quarters since.
  • Sarasin & Partners's Eli Lilly position peaked at $285M in Q2 2024.
  • 1,613 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Sarasin & Partners's 13F filing for Q2 2026, filed 7 Jul 2026.